High risk group
LND is recommended in high-risk EC according to ESMO-ESGO-ESTRO
2016(25) (Table 3). In the high-risk group, the
prevalence of LN involvement is
~19.3%(13). In these patients, worse
prognosis can be assumed without LND, with a need for adjuvant treatment
guided by node-positive disease(13). Furthermore,
without surgical staging including LND, treatment relies on increased
use of external beam radiation therapy (EBRT) which is associated with a
much higher morbidity than with LND alone(33). While
chemotherapy may improve the prognosis of node-positive patients, this
is not applicable to node-negative patients, further demonstrating the
importance of pathological LN assessment in making adjuvant treatment
decisions(33).